Technical Data
I7661-75C
Interferon alpha 2 (alpha 2b), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2b, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765)
20ug
|
Technical Data |
|
I7661-75C |
Interferon alpha 2 (alpha 2b), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2b, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765) |
20ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 165aa of human Interferon-alpha 2b expressed in E.coli is a single, non-glycosylated, polypeptide chain. Molecular Weight: ~19.3kD Biological Activity: The specific activity as determined in a viral resistance assay using bovine kidney MDBK cells was found to be 2.6x108 IU/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.924 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant corresponding to Interferon-alpha 2b as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~19.3kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005 Jul;40(7):722-32. 2. Treatment of early pterygium recurrence with topical administration of interferon alpha-2b. Can J Ophthalmol 2005 Apr;40(2):185-7. 3. p53 protein expression in chronic hepatitis C; effect of interferon alpha 2b therapy. Hepatogastroenterology 2005 Jul-Aug;52(64):1176-9. 4. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005 Jul;12(4):380-5. 5. Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India. Natl Med J India 2005 Mar-Apr;18(2):66-70. 6. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005 May;50(5):970-5.
|
||